Gonadorelin vs PEG-MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Gonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profilePEG-MGF
PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols.
Full profile| Gonadorelin | PEG-MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse | PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 50mcg–200mcg mcg, 2–3x per week subcutaneous | 100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split) |
| Administration | Subcutaneous injection, Intranasal (pulsatile delivery) | Subcutaneous injection (preferred for systemic distribution), Intramuscular injection |
| Key side effects | Injection site reactions, Headache, Nausea, Flushing | Hypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Gonadorelin is research-stage, while PEG-MGF is preclinical only.
- Administration: Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery); PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection.
- Frequency: Gonadorelin is typically 2–3x per week subcutaneous; PEG-MGF is 2x weekly (Monday/Thursday or similar split).
How each works
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
PEG-MGF
PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.